Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Renal Cell Carcinoma Clinical Trial

Official title: Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Status Recruiting

Clinical Trial Summary

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.

...

Clinical Trial Description

Background:

• Disorders under investigation are: Autosomal dominant inherited urologic malignant disorders including: von Hippel-Lindau (VHL), hereditary papillary renal cancer (HPRC), Birt Hogg Dube (BHD) and hereditary leiomyomatosis and renal cell acarcinoma (HLRCC) as well as familial renal cancer.

• Studies have led to the identification and characterization of the VHL, HPRC, FLCN and HLRCC genes.

• The genetic etiology of the most common type of inherited kidney cancer, familial renal cancer (FRC), remains to be determined.

Objectives:

• To characterize the natural and clinical histories of inherited urologic malignant disorders.

• To determine the genetic etiology of hereditary urologic malignant disorders in which the gene variation is unknown, by linkage analysis, positional cloning and evaluation of candidate genes.

• To correlate specific mutations and their associated protein domains with disease phenotypic expression based on parameters including presenting age, clinical manifestations, histopathology and rate of recurrence.

• To identify and describe as yet unknown or uncharacterized inherited urologic malignant disorders.

Eligibility:

• Individuals and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including von Hippel-Lindau (VHL) and hereditary papillary renal carcinoma (HPRC).

• Individuals and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known, specifically hereditary forms of Type II papillary renal cancer, clear cell renal carcinoma, renal oncocytoma, chromophobe renal carcinoma or Birt Hogg Dube.

• Individuals and biologic family members who have urologic malignant diseases of suspected, but not proven genetic etiology, including families with more than one individual affected by the same or related cancers.

Design:

• These rare families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.

• Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.

• We will determine if there is a relationship between mutation and disease manifestations and phenotype. ;

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Clear Cell Renal Cancer
• Kidney Cancer
• Kidney Neoplasms
• Renal Cell Carcinoma
• Urologic Malignant Disorders
• Von Hippel-Lindau Disease

• NCT number: NCT00001238
• Study type: Observational
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Deborah A Nielsen, R.N.
• Phone: (240) 760-6247
• Email: deborah.nielsen@nih.gov
• Status: Recruiting
• Start date: December 5, 1990